SFM
Sphera Funds Management Portfolio holdings
AUM
$382M
This Quarter Return
+6.78%
1 Year Return
+0.41%
3 Year Return
+99.29%
5 Year Return
+177.09%
10 Year Return
+575.73%
AUM
$318M
AUM Growth
+$318M
(-44%)
Cap. Flow
-$316M
Cap. Flow
% of AUM
-99.43%
Top 10 Holdings %
Top 10 Hldgs %
49.1%
Holding
82
New
14
Increased
12
Reduced
20
Closed
21
Top Buys
| 1 |
Astria Therapeutics
ATXS
|
$6.99M |
| 2 |
FIVE9
FIVN
|
$6.45M |
| 3 |
SPDR S&P Biotech ETF
XBI
|
$5.81M |
| 4 |
CINC
CinCor Pharma, Inc. Common Stock
CINC
|
$5.05M |
| 5 |
Generac Holdings
GNRC
|
$5.03M |
Top Sells
| 1 |
Eli Lilly
LLY
|
$43.1M |
| 2 |
AstraZeneca
AZN
|
$33.7M |
| 3 |
Sanofi
SNY
|
$31.7M |
| 4 |
Novo Nordisk
NVO
|
$30.4M |
| 5 |
Merck
MRK
|
$27.3M |
Sector Composition
| 1 | Healthcare | 88.5% |
| 2 | Technology | 3.25% |
| 3 | Industrials | 2.93% |
| 4 | Communication Services | 0.13% |
| 5 | Consumer Discretionary | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
AstraZeneca
AZN
$248B
| $27.1M | 5.82% | 400,060 -497,000 | -55% | -$33.7M |
|
|
2
Sanofi
SNY
$121B
| $27.1M | 5.82% | 559,515 -655,000 | -54% | -$31.7M |
|
3
Johnson & Johnson
JNJ
$427B
| $19.4M | 4.16% | 109,831 -106,320 | -49% | -$18.8M |
|
4
Syndax Pharmaceuticals
SNDX
$1.41B
| $18.1M | 3.88% | 710,561 -112,135 | -14% | -$2.85M |
|
|
5
Merck
MRK
$210B
| $13.4M | 2.87% | 120,600 -246,400 | -67% | -$27.3M |
|
6
Crinetics Pharmaceuticals
CRNX
$2.92B
| $12.3M | 2.64% | 671,644 +45,092 | +7% | +$825K |
|
|
ALBO
7
DELISTED
Albireo Pharma, Inc. Common Stock
ALBO
| $10M | 2.15% | 463,828 +104,828 | +29% | +$2.27M |
|
8
AbbVie
ABBV
$372B
| $9.7M | 2.08% | 60,000 -102,285 | -63% | -$16.5M |
|
|
9
Novo Nordisk
NVO
$251B
| $9.68M | 2.08% | 71,540 -224,900 | -76% | -$30.4M |
|
|
10
Eli Lilly
LLY
$657B
| $9.4M | 2.02% | 25,690 -117,860 | -82% | -$43.1M |
|
11
Kezar Life Sciences
KZR
$28.9M
| $9.19M | 1.97% | 1,305,183 +59,377 | +5% | +$418K |
|
12
Ultragenyx Pharmaceutical
RARE
$2.89B
| $8.51M | 1.83% | 183,696 +10,000 | +6% | +$463K |
|
|
SWTX
13
DELISTED
SpringWorks Therapeutics
SWTX
| $8.24M | 1.77% | 316,625 +15,000 | +5% | +$390K |
|
14
Keros Therapeutics
KROS
$618M
| $7.62M | 1.64% | 158,757 -48,062 | -23% | -$2.31M |
|
15
Arcellx
ACLX
$3.85B
| $7.36M | 1.58% | 237,488 -96,592 | -29% | -$2.99M |
|
|
16
Astria Therapeutics
ATXS
$349M
| $6.99M | 1.5% | +469,340 | New | +$6.99M |
|
|
PNT
17
DELISTED
POINT Biopharma Global Inc. Common Stock
PNT
| $6.94M | 1.49% | 952,642 -100,200 | -10% | -$730K |
|
18
Kura Oncology
KURA
$686M
| $6.93M | 1.49% | 558,287 -231,665 | -29% | -$2.87M |
|
19
Immatics
IMTX
$619M
| $6.8M | 1.46% | 780,852 -14,554 | -2% | -$127K |
|
|
CINC
20
DELISTED
CinCor Pharma, Inc. Common Stock
CINC
| $6.51M | 1.4% | 529,640 +410,690 | +345% | +$5.05M |
|
|
21
FIVE9
FIVN
$2.08B
| $6.45M | 1.38% | +95,000 | New | +$6.45M |
|
22
Altimmune
ALT
$338M
| $6.26M | 1.34% | 380,298 -220,000 | -37% | -$3.62M |
|
|
CNCE
23
DELISTED
Concert Pharmaceuticals, Inc.
CNCE
| $5.86M | 1.26% | 1,002,783 +50,000 | +5% | +$292K |
|
|
24
SPDR S&P Biotech ETF
XBI
$5.07B
| $5.81M | 1.25% | +70,000 | New | +$5.81M |
|
|
25
Generac Holdings
GNRC
$10.9B
| $5.03M | 1.08% | +50,000 | New | +$5.03M |
|